SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by GlaxoSmithKline plc on August 5, 2021, for the month of August 2021. The filing serves as a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notice regarding share issuance rather than a financial results report.
Material Changes
The material change reported is the application for the admission of 3,230,000 Ordinary Shares of 25p each to the Official List of the London Stock Exchange. These shares are being reserved under an existing block listing for issuance under the GlaxoSmithKline plc Share Save Plan 2012 and the 2017 Deferred Annual Bonus Plan.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or a discussion of risks and contingencies. It notes that the new shares will rank pari passu with existing Ordinary Shares and that admission is expected to be effective on August 6, 2021.
Key Facts for Investor Verification
- 3,230,000 new Ordinary Shares are being issued under employee incentive plans.
- Admission to the Official List is expected on August 6, 2021.
- The application was made to the Financial Conduct Authority and the London Stock Exchange plc.
- No financial performance data is included in this specific filing.